Clinical Trial Update: A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations [Phase 2]

View source ↗

Summary

Phase 2 baseline-controlled study evaluating the safety and efficacy of PTX-022 topical sirolimus gel for cutaneous venous malformations. The study status is AC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Venous Malformations

Drugs mentioned

• PTX-022 topical gel 3.9% (sirolimus) (sirolimus)

Snippet

Sponsor: Palvella Therapeutics, Inc. | Conditions: Cutaneous Venous Malformations | Phase 2 | Status: ACTIVE_NOT_RECRUITING